We have focused on HIV-1 entry into cells, a process which is initiated by fusion between the viral envelope and the host cell membrane. Interaction of HIV-1 envelope glycoproteins (gp120-gp41) with host cell CD4 and additional co-receptors such as CXCR4 and CCR5, that determine the tropism of different HIV-1 isolates, triggers this fusion cascade. Several viral envelope glycoprotein oligomers assemble into a viral fusion machine which forms a molecular scaffold responsible for bringing the viral membrane close to the target cell membrane, and creating the architecture that enables lipid bilayers to merge. Triggering the fusion machine results in drastic conformational changes in viral envelope glycoproteins. The fusion reaction then undergoes multiple steps before the final event occurs which allows delivery of the nucleocapsid into the cell. Our overall approach to the elucidation of mechanisms of (gp120-gp41)-mediated membrane fusion involves a dissection of steps in the fusion cascade using spectrofluorometry and quantitative fluorescence video microscopy, and analysis of the kinetic intermediates using a variety of biochemical, biophysical, virological, and molecular and cell biological techniques. We have examined mutations in the ectodomain of the HIV-1 transmembrane glycoprotein gp41 within a region immediately adjacent to the membrane-spanning domain for their effect on the outcome of the fusion cascade. Using our recently-developed 3 color assay we have assessed the ability of the mutant gp41's to transfer lipid and small solutes from susceptible target cells to the gp120-gp41-expressing cells. We found an interesting phenotype that was not capable of inducing syncytia formation but still mediated dye transfer indicating that the fusion cascade was blocked beyond the stage of small fusion pore formation. To analyze the biochemical nature of intermediates and identify domains of HIV-1 gp41 which are involved in the operation of the HIV-1 fusion machine we have applied photosensitized labeling. The method is based on activation of a hydrophobic probe Iodo-Naphthyl-Azide(INA), that rapidly partitions into the membrane bilayer of virus and cells, by a membrane-incorporated fluorescent analog. Using this technique, INA labeling of gp41 can be confined to the domains inserted into the target membrane. We have achieved efficient and reproducible preparative scale purification of gp41 in quantities sufficient for analysis by MALDI-MS or microsequencing. In our studies on the role of the target membrane we have obtained evidence that the fusion machine may assemble in glycosphingolipid-enriched microdomains in the target membrane. Evidence for this concept is based on our finding that treatment of susceptible cell with a specific inhibitor of glycosphingolipid biosynthesis affects HIV-1 infection and fusion, and that this activity can be recovered following addition of a purified Globotriaosylceramide to the impaired cells. The implication is that inhibitors of the glycosphingolipid biosynthetic pathway(s) or of glycosphingolipid-mediated interactions of HIV-1 with the cell surface may prevent HIV infection. Z01 BC 08303-28

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC008303-28
Application #
6433088
Study Section
(LECB)
Project Start
Project End
Budget Start
Budget End
Support Year
28
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Jacobs, Amy; Garg, Himanshu; Viard, Mathias et al. (2008) HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine 26:3026-35
Dimitrov, Antony S; Jacobs, Amy; Finnegan, Catherine M et al. (2007) Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46:1398-401
Jacobs, Amy; Quraishi, Omar; Huang, Xicai et al. (2007) A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex. J Biol Chem 282:32406-13
Garg, Himanshu; Joshi, Anjali; Freed, Eric O et al. (2007) Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem 282:16899-906
Blumenthal, Robert; Dimitrov, Dimiter S (2007) Targeting the sticky fingers of HIV-1. Cell 129:243-5
Fox, T E; Finnegan, C M; Blumenthal, R et al. (2006) The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci 63:1017-23
Rawat, Satinder Singh; Viard, Mathias; Gallo, Stephen A et al. (2006) Sphingolipids, cholesterol, and HIV-1: a paradigm in viral fusion. Glycoconj J 23:189-97
Finnegan, Catherine M; Blumenthal, Robert (2006) Fenretinide inhibits HIV infection by promoting viral endocytosis. Antiviral Res 69:116-23
Wexler-Cohen, Yael; Johnson, Benitra T; Puri, Anu et al. (2006) Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem 281:9005-10
Gallo, Stephen A; Wang, Wei; Rawat, Satinder S et al. (2006) Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 281:18787-92

Showing the most recent 10 out of 42 publications